Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotinamide + tryptophan is a combination of two nutrients—nicotinamide (a form of vitamin B3) and the essential amino acid tryptophan—used primarily as a dietary supplement. This combination has been studied for its potential antidepressant effects, particularly in patients with unipolar depression. Nicotinamide is included to inhibit the peripheral breakdown of tryptophan by reducing liver tryptophan 2,3-dioxygenase activity, thereby increasing plasma levels of tryptophan and enhancing its availability for serotonin synthesis in the brain. Clinical studies suggest that this combination may be as effective as imipramine (a tricyclic antidepressant) when dosed appropriately, with efficacy linked to increased plasma tryptophan concentrations[1][2][3]. The supplement has also been evaluated alongside vitamin B6 for mood improvement in healthy subjects[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotinamide + tryptophan.